Latest construction plan continues CDMO’s vision for biopharma expansion
Thermo Fisher Scientific Inc., a contract development and manufacturing organization (CDMO), will be establishing a manufacturing facility in Nashville, TN, for the production of single-use technologies (SUT) products targeted towards the biopharma industry. This investment will supplement a previously announced expansion to address demand in the bioprocessing market, and is expected to more than double the company's SUT manufacturing capacity, the CDMO notes.
The first phase of construction will begin by Q2 of 2022.
Specifically, the Nashville site is part of Thermo Fisher's more than $650 million capital investment to grow its bioprocessing production capabilities across 11 manufacturing sites and three different continents in North America, Europe and Asia. Additional capacity will be added later this year, with the completion of expansion projects in Logan, UT, Suzhou, China, and a new SUT manufacturing site in Singapore.
"Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single-use platform. This has created incredible demand for our SUT products," says Michel Lagarde, executive vice president of Thermo Fisher Scientific. "The site in Nashville will be critical in Thermo Fisher's global network to continue to support the biopharma industry's work in developing life-saving biologics and vaccines."